Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT)

John DiPersio, Brenda W Cooper, Hyung C Suh, Divya Koura, Lea Bernard, Nirali N. Shah, Roland B. Walter, Miguel-Angel Perales, Markus Mapara, Roni Tamari, Michael R. Loken, Kyle Breitschwerdt, Sritama Nath, Glen D Raffel, Guenther Koehne

Blood (2023) 142 (Supplement 1): 483.

https://doi.org/10.1182/blood-2023-190037

Published: 2023

Journal Articles

Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia

Blood (2023) 142 (Supplement 1): 1053.

https://doi.org/10.1182/blood-2023-190534

Published: 2023

Journal Articles

Reduced Early Mortality with Daratumumab-Based Frontline Therapy in Systemic AL Amyloidosis- Experience from the Columbia Amyloidosis Multidisciplinary Program

Rajshekhar Chakraborty, Divaya Bhutani, Markus Mapara, Ran Reshef, Mathew S Maurer, Jai Radhakrishnan, Suzanne Lentzsch

Blood (2023) 142 (Supplement 1): 4780.

https://doi.org/10.1182/blood-2023-187214

Published: 2023

Journal Articles

Synergistic Anti-Tumor Effects in RAS Mut Multiple Myeloma By Targeting MAP4K2 and RAS Pathways

Jing Fu, Shirong Li, Guifen Liu, Huihui MA, Christophe Marcireau, Markus Mapara, Suzanne Lentzsch

Blood (2023) 142 (Supplement 1): 6618.

https://doi.org/10.1182/blood-2023-190740

Published: 2023

Journal Articles

AsCas12a Gene Editing of HBG1/2 Promoters with EDIT-301 Results in Rapid and Sustained Normalization of Hemoglobin and Increased Fetal Hemoglobin in Patients with Severe Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia

Rabi Hanna, Haydar Frangoul, Christopher McKinney, Luis Pineiro, Markus Mapara, Jignesh Dalal, Kai-Hsin Chang, Michael Jaskolka, Keunpyo Kim, Daphne L. Farrington, Maha Wally, Baisong Mei, Adebayo Lawal, Olubunmi O. Afonja, Mark C. Walters

Blood (2023) 142 (Supplement 1): 4996.

https://doi.org/10.1182/blood-2023-187397

Published: 2023

Journal Articles

Excellent PFS and OS of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib, Bendamustine, and Dexamethasone (KBD): A 6.5 Year Follow-up

Michael Sang Hughes, Siyang Leng, Rajshekhar Chakraborty, Divaya Bhutani, Markus Mapara, Shahzad Raza, Suzanne Lentzsch

Blood (2023) 142 (Supplement 1): 6576.

https://doi.org/10.1182/blood-2023-182842

Published: 2023

Journal Articles

Post CAR-T Peripheral Lymphocytosis and Its Kinetics Are a Potential Biomarker for Response and Immune Mediated Toxicities

Mateo Mejia Saldarriaga, Caitlin Unkenholz, Joshua A Fein, Jorge Monge, Cara Rosenbaum, Roger Pearse, Markus Mapara, Giorgio Inghirami, Suzanne Lentzsch, Ran Reshef, Ruben Niesvizky, Mark Bustoros

Blood (2023) 142 (Supplement 1): 3341.

https://doi.org/10.1182/blood-2023-187832

Published: 2023

Journal Articles

Efficacy, Safety, and Health-Related Quality of Life (HRQOL) in Patients with Sickle Cell Disease (SCD) Who Have Received Lovotibeglogene Autotemcel (Lovo-cel) Gene Therapy: Up to 60 Months of Follow-up

Julie Kanter, Alexis A. Thompson, Janet L. Kwiatkowski, Suhag Parikh, Markus Mapara, Stacey Rifkin-Zenenberg, Banu Aygun, Kimberly A. Kasow, Ashish O. Gupta, Lixin Zhang, Emily Sheldon-Waniga, Meghan Gallagher, Katiana Gruppioni, Anjulika Chawla, Heidi Elliot, Francis J. Pierciey, Mark C. Walters, John F. Tisdale

Blood (2023) 142 (Supplement 1): 1051.

https://doi.org/10.1182/blood-2023-174229

Published: 2023

Journal Articles

Improvements in Health-Related Quality of Life after Exagamglogene Autotemcel in Patients with Severe Sickle Cell Disease

Akshay Sharma, Haydar Frangoul, Markus Mapara, Suzan Imren, Nanxin Li, Tina Liu, Jaime Rubin, Daoyuan Shi, William Hobbs, Stephan Grupp

Blood (2023) 142 (Supplement 1): 4999.

https://doi.org/10.1182/blood-2023-190203

Published: 2023

Journal Articles

Exagamglogene Autotemcel for Severe Sickle Cell Disease

Blood (2023) 142 (Supplement 1): 1052.

https://doi.org/10.1182/blood-2023-190139

Published: 2023

Journal Articles

Checkpoint Inhibitor PD-1H/VISTA Affects Myeloma Bone Disease By Osteoclast Cytoskeleton Remodeling

Jing Fu, Shirong Li, Huihui MA, Lewis M Brown, Markus Mapara, Suzanne Lentzsch

Blood (2023) 142 (Supplement 1): 6610.

https://doi.org/10.1182/blood-2023-189820

Published: 2023

Journal Articles

Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis

Camille Vanessa Edwards, Nisha Rao, Divaya Bhutani, Markus Mapara, Jai Radhakrishnan, Sofia Shames, Mathew S. Maurer, Siyang Leng, Alan Solomon, Suzanne Lentzsch, Andrew Eisenberger

Blood (2021) 138 (25): 2632–2641.

https://doi.org/10.1182/blood.2020009039

Published: 2021

Includes: Supplemental data

Journal Articles

Analysis of the Phase 1a/b Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients with AL Amyloidosis

Camille V Edwards, MD, Julia Gould, BA, Arielle L Langer, MD MPH, Markus Mapara, MD PhD, Jai Radhakrishnan, MD, Matthew S Maurer, MD, Shahzad Raza, MD, John G Mears, MD, Jonathan S Wall, PhD, Alan Solomon, MD, Suzanne Lentzsch, MD PhD

Blood (2016) 128 (22): 643.

https://doi.org/10.1182/blood.V128.22.643.643

Published: 2016

Journal Articles

Interferon-Gamma Signaling in the Pathogenesis of Idiopathic Pneumonia Syndrome Following Allogeneic Bone Marrow Transplantation

Hui-Hui Ma, PhD, Biin Sung, MS, Caisheng Lu, MDPhD, Liangsong Song, MDPhD, Rika Gomi, MDPhD, Wenzhu Wu, BS, Jing Fu, PhD, Suzanne Lentzsch, MD PhD, Stefan Worgall, MDPhD, Markus Mapara, MD PhD

Blood (2015) 126 (23): 3075.

https://doi.org/10.1182/blood.V126.23.3075.3075

Published: 2015

Journal Articles

Mechanism Study of Matrix Metalloproteinase 13 Effects on Osteoclast Activation and Lytic Bone Lesions in Multiple Myeloma

Jing Fu, PhD, Shirong Li, PhD, G. David Roodman, MD PhD, Markus Mapara, MD PhD, Stephen J. Weiss, MD, Suzanne Lentzsch, MD PhD

Blood (2015) 126 (23): 3009.

https://doi.org/10.1182/blood.V126.23.3009.3009

Published: 2015

Journal Articles

Results of Phase I Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients with AL Amyloidosis

Arielle L Langer, MD MPH, Susanna Miao, Markus Mapara, MD PhD, Jai Radhakrishnan, MD, Mathew S. Maurer, MD, Shahzad Raza, MD, John G. Mears, MD, Alan Solomon, MD, Suzanne Lentzsch, MD PhD

Blood (2015) 126 (23): 188.

https://doi.org/10.1182/blood.V126.23.188.188

Published: 2015

Journal Articles

IMiD® Compounds Affect the Hematopoiesis Via CRBN Dependent Degradation of IKZF1 Protein in CD34 + Cells

Shirong Li, PhD, Jing Fu, PhD, Markus Mapara, MD PhD, Suzanne Lentzsch, MD PhD

Blood (2014) 124 (21): 418.

https://doi.org/10.1182/blood.V124.21.418.418

Published: 2014

Journal Articles

Pomalidomide Induces Mir-125b with Subsequent Downregulation of P53 in CD34 + cells Conferring Decreased Apoptosis: A Potential Mechanism of Secondary Primary Malignancies

Yijie Zheng, PhD, Shirong Li, PhD, Jing Fu, PhD, Markus Mapara, MD PhD, Suzanne Lentzsch, MD PhD

Blood (2014) 124 (21): 3437.

https://doi.org/10.1182/blood.V124.21.3437.3437

Published: 2014

Journal Articles

Lenalidomide and Dexamethasone Alone Is Equivalent To Lenalidomide and Dexamethasone With Autologous Stem Cell Transplant In Newly Diagnosed Multiple Myeloma: Interim Study Results Of a Randomized Trial

Jordan M. Schecter, MD, Kristen Kipps, MD, Amy O'Sullivan, BS, BSN, MSW, Kent A. Griffith, MPH, MS, Daniel Normolle, PhD, Markus Mapara, MD, PhD, Robert Redner, MD, Suzanne Lentzsch, MD, PhD

Blood (2013) 122 (21): 3180.

https://doi.org/10.1182/blood.V122.21.3180.3180

Published: 2013

Journal Articles

IFN-γ/STAT1-Dependent Regulation Of Antigen Presenting Cell (APC) Function: Role In Graft-Versus-Host Disease (GVHD)

Caisheng Lu, PHD, Huihui Ma, PhD, Shirong Li, PhD, Suzanne Lentzsch, MD, PhD, Markus Mapara, MD, PhD

Blood (2013) 122 (21): 3252.

https://doi.org/10.1182/blood.V122.21.3252.3252

Published: 2013

NARROW

Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia

Reduced Early Mortality with Daratumumab-Based Frontline Therapy in Systemic AL Amyloidosis- Experience from the Columbia Amyloidosis Multidisciplinary Program

Synergistic Anti-Tumor Effects in RAS Mut Multiple Myeloma By Targeting MAP4K2 and RAS Pathways

AsCas12a Gene Editing of HBG1/2 Promoters with EDIT-301 Results in Rapid and Sustained Normalization of Hemoglobin and Increased Fetal Hemoglobin in Patients with Severe Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia

Excellent PFS and OS of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib, Bendamustine, and Dexamethasone (KBD): A 6.5 Year Follow-up

Post CAR-T Peripheral Lymphocytosis and Its Kinetics Are a Potential Biomarker for Response and Immune Mediated Toxicities

Efficacy, Safety, and Health-Related Quality of Life (HRQOL) in Patients with Sickle Cell Disease (SCD) Who Have Received Lovotibeglogene Autotemcel (Lovo-cel) Gene Therapy: Up to 60 Months of Follow-up

Improvements in Health-Related Quality of Life after Exagamglogene Autotemcel in Patients with Severe Sickle Cell Disease

Exagamglogene Autotemcel for Severe Sickle Cell Disease

Checkpoint Inhibitor PD-1H/VISTA Affects Myeloma Bone Disease By Osteoclast Cytoskeleton Remodeling

Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis

Analysis of the Phase 1a/b Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients with AL Amyloidosis

Interferon-Gamma Signaling in the Pathogenesis of Idiopathic Pneumonia Syndrome Following Allogeneic Bone Marrow Transplantation

Mechanism Study of Matrix Metalloproteinase 13 Effects on Osteoclast Activation and Lytic Bone Lesions in Multiple Myeloma

Results of Phase I Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients with AL Amyloidosis

IMiD® Compounds Affect the Hematopoiesis Via CRBN Dependent Degradation of IKZF1 Protein in CD34 + Cells

Pomalidomide Induces Mir-125b with Subsequent Downregulation of P53 in CD34 + cells Conferring Decreased Apoptosis: A Potential Mechanism of Secondary Primary Malignancies

Lenalidomide and Dexamethasone Alone Is Equivalent To Lenalidomide and Dexamethasone With Autologous Stem Cell Transplant In Newly Diagnosed Multiple Myeloma: Interim Study Results Of a Randomized Trial

IFN-γ/STAT1-Dependent Regulation Of Antigen Presenting Cell (APC) Function: Role In Graft-Versus-Host Disease (GVHD)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only